3 ASX All Ordinaries shares leaping by more than 10% on Friday

Here are three ASX All Ordinaries shares that have rocketed higher.

| More on:
Three people sit on safe cheering with pizza on table

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • These three ASX shares are all jumping higher
  • The market is reversing some of the declines seen in recent days, weeks and months
  • Cettire, Block and 5E Advanced Materials are three of those surging higher

The S&P/ASX All Ordinaries Index (ASX: XAO) is rising 1.86% at the time of writing. There are a few ASX All Ordinaries shares that have also gone up strongly.

In plenty of cases, this is just a reversal of the declines that companies saw in the previous day(s).

But these three businesses are seeing very large gains:

Cettire Ltd (ASX: CTT)

The Cettire share price is currently up by 16.5%. However, the company is still down by 85% since the start of 2022.

Cettire is a global e-commerce player that sells luxury personal goods. It has a catalogue of around 1,700 luxury brands and 200,000 products across clothing, shoes, bags, and accessories.

The most recent news that investors have seen from the ASX All Ordinaries share was its update for the third quarter of FY22.

Year-on-year, sales revenue increased by 163% to $48.7 million, the number of active customers rose by 185% to 246,800 and the number of unique website visits soared by 269%. The company said more than 50% of gross revenue came from repeat purchasers.

Block Inc (ASX: SQ2)

The Block Inc share price is up by 14.2% at the time of writing. However, Block shares are down around 35% since listing on the ASX in January 2022.

This company is a payments business that includes Square and the buy now, pay later business Afterpay.

Block recently announced its quarterly update for the three months to 31 March 2022. It reported that transaction-based revenue rose by around 28% to US$1.23 billion. Subscription and service-based revenue increased by 72% to US$959.6 million.

However, Bitcoin revenue dropped around 50% to US$1.73 billion. This led to total net revenue falling by 22% to US$3.96 billion.

The All Ordinaries ASX share reported a net loss for shareholders of US$204 million.

5E Advanced Materials Inc (ASX: 5EA)

The 5E Advanced Materials share price is currently up by 11.2%. Since the company listed on the ASX on 1 March 2022, 5E Advanced Materials shares are up 7.8%. However, they are still down more than 12% since 4 May 2022.

This business wants to become a vertically integrated global leader and supplier of boron specialty and advanced materials to enable decarbonisation. It's expecting boron and lithium products will target applications for electric transportation, clean energy, food, and domestic security.

The latest that the ASX All Ordinaries share has revealed was its update for the three months to 31 March.

It said that average boric acid prices increased by more than 50% during the first three months of the 2022 calendar year. It noted there are favourable market dynamics and "continued strong demand".

The company wants to become an "important participant" in the US lithium market. A small-scale boron facility targets mechanical completion in the last quarter of the 2022 calendar year, after 'breaking ground' in April 2022.

Planning for the proposed large-scale complex is progressing.

A letter of intent has been signed for boron advanced material that focuses on industrial and military applications.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Block, Inc. and Cettire Limited. The Motley Fool Australia has positions in and has recommended Block, Inc. The Motley Fool Australia has recommended Cettire Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »